Clinical Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Darexaban, an Oral Direct Factor Xa Inhibitor, in Healthy Elderly Japanese Subjects

Publisher： John Wiley & Sons Inc

E-ISSN： 2160-7648|2|4|328-335

ISSN： 2160-763X

Source： Clinical Pharmacology In Drug Development, Vol.2, Iss.4, 2013-10, pp. : 328-335

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacokinetics and Pharmacodynamics of the Direct Oral Thrombin Inhibitor Dabigatran in Healthy Elderly Subjects

By Stangier Joachim  

Clinical Pharmacokinetics, Vol. 47, Iss. 1, 2008-01 ,pp. : 47-59

Adis International

Access to resources Recommend Favorite

Pharmacokinetics and Pharmacodynamics of Rivaroxaban – An Oral, Direct Factor Xa Inhibitor

By  

Current Clinical Pharmacology, Vol. 9, Iss. 1, 2014-02 ,pp. : 75-83

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacokinetics, Pharmacodynamics, Pharmacogenomics, Safety, and Tolerability of Avatrombopag in Healthy Japanese and White Subjects

By  

Clinical Pharmacology In Drug Development, Vol. 7, Iss. 2, 2018-02 ,pp. : 188-195

John Wiley & Sons Inc

Access to resources Recommend Favorite

Darexaban (YM150), an oral direct factor Xa inhibitor, has no effect on the pharmacokinetics of digoxin

By Kadokura Takeshi   Groenendaal Dorien   Heeringa Marten   Mol Roelof   Verheggen Frank   Garcia-Hernandez Alberto   Onkels Hartmut  

European Journal of Drug Metabolism and Pharmacokinetics, Vol. 39, Iss. 1, 2014-03 ,pp. : 1-9

Springer Publishing Company

Access to resources Recommend Favorite

Novel oral anticoagulants: focus on the direct factor Xa inhibitor darexaban

By Apostolakis Stavros   Lip Gregory YH  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 7, 2012-07 ,pp. : 1057-1064

Informa Healthcare

Access to resources Recommend Favorite